Payam Nahid, MD, MPH
Professor
Medicine
School of Medicine

With over two decades of experience in global health, he specializes in clinical trials and translational research on TB and HIV/TB co-infection. Dr. Nahid has led international programs funded by NIH, CDC, USAID, and BMGF to develop new TB diagnostics and treatments. In 2009, he co-founded the Vietnam National TB Programme-UCSF Research Collaboration Unit to promote equitable international research activities. As the Senior Research Advisor for the USAID-funded Supporting, Mobilizing and Accelerating Research for Tuberculosis Elimination (SMART4TB), Dr. Nahid directs the consortium's research strategies. Dr. Nahid serves as the Director of the UCSF Center for Tuberculosis and co-leads the NIAID-funded UCSF-UC Berkeley TB Research Advancement Center (UC TRAC), which trains early-stage TB investigators. Dr. Nahid has led WHO Task Forces and international practice guidelines. He is an appointed member of the WHO Strategic and Technical Advisory Group on TB (STAG TB).

• Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens…
• Longitudinal analysis of host protein serum signatures of treatment and recovery in pulmonary tuberculosis.
  PloS one 2024 Powell SM, Jarsberg LG, Zionce ELM, Anderson LN, Gritsenko MA, Nahid P, Jacobs JM
• Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
  PLoS medicine 2024 Semitala FC, Kadota JL, Musinguzi A, Welishe F, Nakitende A, Akello L, Kunihira Tinka L, Nakimuli J, Ritar Kasidi J, Bishop O, Nakasendwa S, Baik Y, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, …
• Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa.
  The Lancet. Global health 2024 Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM, R2D2 TB …
• Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2024 Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, Phillips P, Nahid P, Cattamanchi A, Marx FM, Denkinger CM, Dowdy DW
• Tuberculosis treatment monitoring tests during routine practice: study design guidance.
  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2024 MacLean EL, Zimmer AJ, den Boon S, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM
• Blazing the trail for innovative tuberculosis diagnostics.
  Infection 2023 Yerlikaya S, Broger T, Isaacs C, Bell D, Holtgrewe L, Gupta-Wright A, Nahid P, Cattamanchi A, Denkinger CM
• Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
  Trials 2023 Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De …
• Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice.
  mBio 2023 Wynn EA, Dide-Agossou C, Reichlen M, Rossmassler K, Al Mubarak R, Reid JJ, Tabor ST, Born SEM, Ransom MR, Davidson RM, Walton KN, Benoit JB, Hoppers A, Loy DE, Bauman AA, Massoudi LM, Dolganov G, …
• Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
  Lancet (London, England) 2023 Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, …
• A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
  American journal of respiratory and critical care medicine 2023 Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung …
• Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Solans BP, Béranger A, Radtke K, Mohamed A, Mirzayev F, Gegia M, Linh NN, Schumacher SG, Nahid P, Savic RM
• Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.
  American journal of respiratory and critical care medicine 2023 Velásquez GE, Nahid P
• Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
  The Lancet. Respiratory medicine 2023 Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D
• Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis in mice.
  bioRxiv : the preprint server for biology 2023 Wynn EA, Dide-Agossou C, Reichlen M, Rossmassler K, Al Mubarak R, Reid JJ, Tabor ST, Born SEM, Ransom MR, Davidson RM, Walton KN, Benoit JB, Hoppers A, Bauman AA, Massoudi LM, Dolganov G, Nahid P, …
• Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023 Huddart S, Asege L, Jaganath D, Golla M, Dang H, Lovelina L, Derendinger B, Andama A, Christopher DJ, Nhung NV, Theron G, Denkinger CM, Nahid P, Cattamanchi A, Yu C
• Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review protocol.
  BMJ open 2023 Yerlikaya S, Holtgrewe LM, Broger T, Isaacs C, Nahid P, Cattamanchi A, Denkinger CM
• Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2023 Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott …
• Circulating Cell-Free RNA in Blood as a Host Response Biomarker for the Detection of Tuberculosis.
  medRxiv : the preprint server for health sciences 2023 Chang A, Loy CJ, Lenz JS, Steadman A, Andama A, Nhung NV, Yu C, Worodria W, Denkinger CM, Nahid P, Cattamanchi A, De Vlaminck I
• A comparison of clinical development pathways to advance tuberculosis regimen development.
  BMC infectious diseases 2022 Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM
• Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2022 Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips PPJ, Bryant K, Scott N, Vernon…
• Interventions to enhance treatment adherence and retention in care for HIV-TB.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 Hudson M, Alipanah N, Singh S, Nahid P
• The scientific response to TB - the other deadly global health emergency.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 Chaisson RE, Frick M, Nahid P
• Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children.
  American journal of respiratory and critical care medicine 2021 Blount RJ, Phan H, Trinh T, Dang H, Merrifield C, Zavala M, Zabner J, Comellas AP, Stapleton EM, Segal MR, Balmes J, Nhung NV, Nahid P
• Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2021 Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, Allwood B, Byrne AL, Mortimer K, Wallis RS, Fox GJ, Leung CC, Chakaya JM, Seaworth B, Rachow A, Marais BJ, Furin J, Akkerman …
• Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden.
  Microbiology spectrum 2021 Musisi E, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ssesolo AW, Kaswabuli S, Byanyima P, Sanyu I, Zawedde J, Worodria W, Voskuil MI, Savic RM, Nahid P, Davis JL, Huang L, Moore CM, Walter ND
• A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.
  Trials 2021 Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ
• Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens.
  Nature communications 2021 Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang …
• Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region.
  PloS one 2021 Jarsberg LG, Kedia K, Wendler J, Wright AT, Piehowski PD, Gritsenko MA, Shi T, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Keane J, Jacobs JM, Nahid P
• Reply to Chang and Yew.
  American journal of respiratory and critical care medicine 2020 Sotgiu G, Battista Migliori G, Menzies D, Mase S, Chorba T, Seaworth B, Nahid P
• Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
  Implementation science : IS 2020 Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba …
• Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis.
  Annals of the American Thoracic Society 2020 Berger CA, Alipanah N, Kheir F, Ruminjo JK, Nahid P, Thomson C
• Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection.
  Journal of clinical microbiology 2020 Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM
• The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
  The European respiratory journal 2020 Cegielski JP, Nahid P, Sotgiu G
• Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
  The Lancet. Respiratory medicine 2020 Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid…
• Triumph and Tragedy of 21st Century Tuberculosis Drug Development.
  The New England journal of medicine 2020 Thwaites G, Nahid P
• Advances in clinical trial design: Weaving tomorrow's TB treatments.
  PLoS medicine 2020 Lienhardt C, Nunn A, Chaisson R, Vernon AA, Zignol M, Nahid P, Delaporte E, Kasaeva T
• High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
  Contemporary clinical trials 2020 Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, …
• The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.
  PLoS medicine 2019 Vernon A, Fielding K, Savic R, Dodd L, Nahid P
• Treatment of Drug-Susceptible Tuberculosis.
  Clinics in chest medicine 2019 Zha BS, Nahid P
• Residential urban tree canopy is associated with decreased mortality during tuberculosis treatment in California.
  The Science of the total environment 2019 Blount RJ, Pascopella L, Barry P, Zabner J, Stapleton EM, Flood J, Balmes J, Nahid P, Catanzaro DG
• Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.
  PLoS medicine 2019 Lienhardt C, Vernon AA, Cavaleri M, Nambiar S, Nahid P
• Multidrug-resistant tuberculosis - Authors' reply.
  Lancet (London, England) 2019 Menzies D, Benedetti A, Migliori GB, Nahid P, Seaworth B
• Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening.
  Diagnostics (Basel, Switzerland) 2019 Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P
• Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients.
  PloS one 2019 Broger T, Tsionksy M, Mathew A, Lowary TL, Pinter A, Plisova T, Bartlett D, Barbero S, Denkinger CM, Moreau E, Katsuragi K, Kawasaki M, Nahid P, Sigal GB
• Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
  PLoS medicine 2019 Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ
• Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.
  American journal of respiratory and critical care medicine 2019 Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens…
• Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
  Nature medicine 2019 Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM
• A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis.
  Journal of clinical microbiology 2018 Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, Tsionsky M, Zheng RB, Plisova T, Shen K, Katsuragi K, Choudhary A, Honnen WJ, Nahid P, Denkinger CM, Broger T
• The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients.
  The clinical respiratory journal 2018 Korkmaz Ekren P, Töreyin ZN, Nahid P, Doskaya M, Caner A, Turgay N, Zeytinoglu A, Toz S, Bacakoglu F, Guruz Y, Erensoy S
• Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
  Lancet (London, England) 2018 Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera…
• Tuberculosis.
  Emergency Management of Infectious Diseases 2018 Robert Blount, Payam Nahid, Adithya Cattamanchi
• Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.
  Tuberculosis (Edinburgh, Scotland) 2018 Kedia K, Wendler JP, Baker ES, Burnum-Johnson KE, Jarsberg LG, Stratton KG, Wright AT, Piehowski PD, Gritsenko MA, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Jacobs JM, Nahid P
• Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.
  PLoS medicine 2018 Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P
• Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputum.
  BMC infectious diseases 2018 Walter ND, Moore CM, Kayigire XA, Dide-Agossou C, Worodria W, Huang L, Everett CK, Schoolnik GS, Nahid P, Davis JL
• Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis.
  PloS one 2018 Nahid P, Jarlsberg LG, Kato-Maeda M, Segal MR, Osmond DH, Gagneux S, Dobos K, Gold M, Hopewell PC, Lewinsohn DM
• Traffic-Related Air Pollution and All-Cause Mortality during Tuberculosis Treatment in California.
  Environmental health perspectives 2017 Blount RJ, Pascopella L, Catanzaro DG, Barry PM, English PB, Segal MR, Flood J, Meltzer D, Jones B, Balmes J, Nahid P
• Second generation multiple reaction monitoring assays for enhanced detection of ultra-low abundance Mycobacterium tuberculosis peptides in human serum.
  Clinical proteomics 2017 Mehaffy C, Dobos KM, Nahid P, Kruh-Garcia NA
• Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2017 Feng JY, Jarlsberg LG, Salcedo K, Rose J, Janes M, Lin SG, Osmond DH, Jost KC, Soehnlen MK, Flood J, Graviss EA, Desmond E, Moonan PK, Nahid P, Hopewell PC, Kato-Maeda M
• Impact of Euro-American sublineages of Mycobacterium tuberculosis on new infections among named contacts.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2017 Feng JY, Jarlsberg LG, Rose J, Grinsdale JA, Janes M, Higashi J, Osmond DH, Nahid P, Hopewell PC, Kato-Maeda M
• Vitamin D Deficiency in Patients Referred for Evaluation of Obstructive Sleep Apnea.
  Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2017 Salepci B, Caglayan B, Nahid P, Parmaksiz ET, Kiral N, Fidan A, Comert SS, Dogan C, Gungor GA
• The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.
  The Lancet. Respiratory medicine 2017 Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, …
• Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
  Clinical pharmacology and therapeutics 2017 Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE, Tuberculosis Trials Consortium of the Centers for Disease Control…
• First in vivo magnetic particle imaging of lung perfusion in rats.
  Physics in medicine and biology 2017 Zhou XY, Jeffris KE, Yu EY, Zheng B, Goodwill PW, Nahid P, Conolly SM
• Target regimen profiles for treatment of tuberculosis: a WHO document.
  The European respiratory journal 2017 Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M
• Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.
  PLoS medicine 2017 Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW
• Tuberculosis Treatment.
  International Encyclopedia of Public Health 2017 Payam Nahid, Philip C. Hopewell
• Treatment of Drug-Susceptible Tuberculosis.
  Annals of the American Thoracic Society 2016 Dela Cruz CS, Lyons PG, Pasnick S, Weinstock T, Nahid P, Wilson KC, Thomson CC
• Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016 Alipanah N, Cattamanchi A, Menzies R, Hopewell PC, Chaisson RE, Nahid P
• Reply to Alffenaar et al.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Peloquin CA, Dorman SE, Vernon A, Battista Migliori G, Nahid P
• Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.
  Journal of clinical microbiology 2016 Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P
• Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, …
• The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis.
  The European respiratory journal 2016 Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB
• Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.
  BMC public health 2016 Blount RJ, Tran MC, Everett CK, Cattamanchi A, Metcalfe JZ, Connor D, Miller CR, Grinsdale J, Higashi J, Nahid P
• Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients.
  The Journal of infectious diseases 2016 Walter ND, de Jong BC, Garcia BJ, Dolganov GM, Worodria W, Byanyima P, Musisi E, Huang L, Chan ED, Van TT, Antonio M, Ayorinde A, Kato-Maeda M, Nahid P, Leung AM, Yen A, Fingerlin TE, Kechris K, …
• Urban tree coverage associated with reduced mortality among tuberculosis (TB) patients undergoing treatment in California.
  ISEE Conference Abstracts 2016 Robert J Blount*, Lisa Pascopella, Pennan Barry, Dan Meltzer, Jenny Flood, Paul B English, Mark R Segal, Payam Nahid, John Balmes, Donald G Catanzaro
• Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, …
• A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).
  BMC medicine 2016 Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M
• Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016 Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta …
• Challenges in the clinical assessment of novel tuberculosis drugs.
  Advanced drug delivery reviews 2016 Dooley KE, Phillips PP, Nahid P, Hoelscher M
• A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015 Nicol MP, Gnanashanmugam D, Browning R, Click ES, Cuevas LE, Detjen A, Graham SM, Levin M, Makhene M, Nahid P, Perez-Velez CM, Reither K, Song R, Spiegel HM, Worrell C, Zar HJ, Walzl G
• Evaluation of mobile digital light-emitting diode fluorescence microscopy in Hanoi, Viet Nam.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2015 Chaisson LH, Reber C, Phan H, Switz N, Nilsson LM, Myers F, Nhung NV, Luu L, Pham T, Vu C, Nguyen H, Nguyen A, Dinh T, Nahid P, Fletcher DA, Cattamanchi A
• In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection.
  Diagnostic microbiology and infectious disease 2015 Slater M, Tran MC, Platt L, Luu LT, Phan HT, Pham PT, Do TB, Nguyen HT, Gaur RL, Parsonnet J, Cattamanchi A, Luo R, Nahid P, Banaei N
• Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.
  Tuberculosis (Edinburgh, Scotland) 2015 Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P, Tuberculosis Trials Consortium
• Towards tuberculosis elimination: an action framework for low-incidence countries.
  The European respiratory journal 2015 Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van …
• Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.
  The Journal of infectious diseases 2015 Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, …
• Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
  American journal of respiratory and critical care medicine 2015 Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M, …
• Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS.
  PloS one 2014 Kruh-Garcia NA, Wolfe LM, Chaisson LH, Worodria WO, Nahid P, Schorey JS, Davis JL, Dobos KM
• Non-tuberculous mycobacterial infections at San Francisco General Hospital.
  The clinical respiratory journal 2014 Sheu LC, Tran TM, Jarlsberg LG, Marras TK, Daley CL, Nahid P
• Childhood tuberculosis in northern Viet Nam: a review of 103 cases.
  PloS one 2014 Blount RJ, Tran B, Jarlsberg LG, Phan H, Thanh Hoang V, Nguyen NV, Lewinsohn DA, Nahid P
• Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California.
  PloS one 2014 Budzik JM, Jarlsberg LG, Higashi J, Grinsdale J, Hopewell PC, Kato-Maeda M, Nahid P
• Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV.
  Journal of acquired immune deficiency syndromes (1999) 2014 Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, Bangsberg DR, Nahid P, Semitala FC, Hunt PW, Martin JN, Cattamanchi A
• Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.
  Tuberculosis (Edinburgh, Scotland) 2014 Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA
• Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection.
  Journal of the Pediatric Infectious Diseases Society 2014 Chang SH, Nahid P, Eitzman SR
• Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents.
  Journal of infection and public health 2013 Chang SH, Eitzman SR, Nahid P, Finelli ML
• Update in tuberculosis and nontuberculous mycobacterial disease 2012.
  American journal of respiratory and critical care medicine 2013 Menzies D, Nahid P
• Advances in the development of new tuberculosis drugs and treatment regimens.
  Nature reviews. Drug discovery 2013 Zumla A, Nahid P, Cole ST
• Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.
  PloS one 2013 De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA
• Drug-resistant tuberculosis: time for visionary political leadership.
  The Lancet. Infectious diseases 2013 Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, …
• Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
  The Journal of infectious diseases 2012 Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis…
• Update in tuberculosis and nontuberculous mycobacterial disease 2011.
  American journal of respiratory and critical care medicine 2012 Nahid P, Menzies D
• Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis.
  PloS one 2012 Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, Nahid P, Cattamanchi A
• Clinical research and development of tuberculosis diagnostics: moving from silos to synergy.
  The Journal of infectious diseases 2012 Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T,…
• Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.
  Tuberculosis (Edinburgh, Scotland) 2012 Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW
• Mycobacterium tuberculosis lineage--what's in your lungs?
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2012 Kato-Maeda M, Nahid P
• Major Radiation Exposure.
  2012 Denis D. Bensard, Philip F. Stahel, Jorge Cerdá, Babak Sarani, Sajid Shahul, Daniel Talmor, Peter M. Hammer, C. William Schwab, Steven Reynolds, Omar Ahmad, Tsuyoshi Kaneko, Anthony L. Estrera, …
• Mycobacterial Infections in the non-HIV–Infected Patient.
  2012 Melissa Nyendak, Tarek Eid, Payam Nahid, Kevin Winthrop, David Lewinsohn
• CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
  American journal of respiratory and critical care medicine 2011 Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, …
• Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011 Nahid P, Horne DJ, Jarlsberg LG, Reiner AP, Osmond D, Hopewell PC, Bibbins-Domingo K
• Discriminating between latent and active tuberculosis with multiple biomarker responses.
  Tuberculosis (Edinburgh, Scotland) 2011 Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, Nahid P, Ferrari G, Stout JE
• Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2011 Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P
• Sputum monitoring during tuberculosis treatment for predicting outcome Authors' reply.
  The Lancet Infectious Diseases 2011 David J Horne, Sarah E Royce, Masahiro Narita, Payam Nahid, Karen R Steingart
• Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis.
  BMC infectious diseases 2011 Nahid P, Jarlsberg LG, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL
• Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.
  The Lancet. Infectious diseases 2010 Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR
• Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.
  PloS one 2010 Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M, Tuberculosis Trials Consortium
• Novel hot spot of IS6110 insertion in Mycobacterium tuberculosis.
  Journal of clinical microbiology 2010 Kim EY, Nahid P, Hopewell PC, Kato-Maeda M
• Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects.
  American journal of respiratory and critical care medicine 2009 Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P
• Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis.
  Emerging infectious diseases 2009 Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A, Tuberculosis Trials Consortium
• Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009 Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P
• Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis.
  Clinical and vaccine immunology : CVI 2008 Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, Ramsay A, Pai M, Laal S
• Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection.
  Chest 2008 Cattamanchi A, Nahid P, Marras TK, Gotway MB, Lee TJ, Gonzalez LC, Morris A, Webb WR, Osmond DH, Daley CL
• Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples.
  Nursing research 2008 Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B
• On Treatment Outcomes of Patients with HIV and Tuberculosis.
  American Journal of Respiratory and Critical Care Medicine 2008 Payam Nahid, Bouke C. de Jong, Charles L. Daley
• Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective.
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008 Walter ND, Jasmer RM, Grinsdale J, Kawamura LM, Hopewell PC, Nahid P
• Tuberculosis Treatment.
  International Encyclopedia of Public Health 2008 P. Nahid, P.C. Hopewell
• Tuberculosis.
  Emergency Management of Infectious Diseases 2008 Adithya Cattamanchi, Payam Nahid
• Treatment outcomes of patients with HIV and tuberculosis.
  American journal of respiratory and critical care medicine 2007 Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL
• Unusual finding on bronchoscopy: trauma patient identified as a body stuffer.
  Journal of clinical anesthesia 2006 Chang C, Grush A, McClintock DE, Nahid P, Tang JF
• A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection.
  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2006 Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B
• Prevention of tuberculosis in HIV-infected patients.
  Current opinion in infectious diseases 2006 Nahid P, Daley CL
• Advances in the diagnosis and treatment of tuberculosis.
  Proceedings of the American Thoracic Society 2006 Nahid P, Pai M, Hopewell PC
• Clinical practice. Latent tuberculosis infection.
  The New England journal of medicine 2002 Jasmer RM, Nahid P, Hopewell PC